Polymorphisms in the prostate-specific antigen gene promoter do not predict serum prostate-specific antigen levels in African-American men.
A major problem with the use of serum prostate-specific antigen (PSA) in predicting prostate cancer risk is the considerable variability of such measurements. Cramer et al. identified a set of single-nucleotide polymorphisms (SNPs) in the upstream regulatory region of the PSA gene that were each associated with increased promoter activity and serum PSA, further suggesting that genotyping these SNPs could be useful in improving the predictive value of PSA screening. In order to replicate this finding, DNA samples from 475 African-American men were genotyped for the same SNPs and no association was observed with either serum PSA level or prostate cancer diagnosis.
Beebe-Dimmer
J L
JL
Department of Urology, University of Michigan Medical School, Ann Arbor MI, USA. jbeebe@med.umich.edu
Lange
L A
LA
Cain
J E
JE
Lewis
R C
RC
Ray
A M
AM
Sarma
A V
AV
Lange
E M
EM
Cooney
K A
KA
D000328:Adult; D001741:Black or African American / Q000208:ethnology; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics / Q000276:immunology; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011379:Prognosis; D011401:Promoter Regions, Genetic / Q000235:genetics*; D017430:Prostate-Specific Antigen / Q000097:blood* / Q000235:genetics*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000208:ethnology / Q000235:genetics*
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen